Has the ability to provide informed consent to participate in the clinical study before completing any study-related procedures, and has an understanding, ability, and willingness to comply with clinical study procedures and restrictions.
Adults 18 to 70 years.
Adolescents 12 to \<18 years, dependent on geographical location.
Has clinical bleeding phenotype consistent with Glanzmann thrombasthenia (GT) and documentation of either diagnostic laboratory criteria (a) or (b) below:
1. Abnormal platelet aggregometry AND flow cytometry
2. A confirmed genetic mutation in ITGA2B or ITGB3.
Participants have experienced at least four treated bleeding events related to GT within the 12 months prior to Screening.
You may not be if
Prior exposure to sutacimig.
History of clinically significant hypersensitivity associated with monoclonal antibody therapies.
Congenital or acquired bleeding disorders other than GT.
Medical condition (other than GT) that constitutes an increased risk of having uncontrolled bleeding events during the study or other conditions per Investigator discretion.
History of venous or arterial thromboembolic (TE) event or TE disease except for catheter-associated vein thrombosis.